

46. Xu B, Wang C, Wang YL, et al. miR-143 inhibits renal cell carcinoma cells metastatic potential by suppressing ABL2. Kaohsiung Journal of Medical Sciences. 2020; 36(8): 592–8.
47. Seles M, Hutterer G, Kiesslich T, et al. Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma. International Journal of Molecular Sciences. 2016; 17(4): 573.
48. Wang W, Song J, Zhang W, et al. Identification of Long Non-Coding RNA Signatures for Specific Disease-Free Prognosis in Clear Cell Renal Carcinoma. IEEE Access. 2019; 7: 99290–8.
49. Qu L, Wang ZL, Chen Q, et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. European Urology. 2018; 74(6): 756–63.
50. Guan Y, Xu F, Tian J, et al. The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma. BMC Cancer. 2021; 21(1).
51. Broncy L, Paterlini-Bréchet P. Circulating Tumor Cells for the Management of Renal Cell Carcinoma. Diagnostics. 2018; 8(3): 63.

9. ROČNÍK

KNOU2024

KOMPLEXNÍ NOVINKY V ONKOLOGII

Hotel Vienna House Andel's, Stroupežnického 21, Praha 5

17.–18. 5. 2024